Shares of ImmunoCellular Therapeutics Ltd (NYSEAMERICAN:IMUC) saw unusually-high trading volume on Tuesday . Approximately 5,130,167 shares traded hands during trading, an increase of 247% from the previous session’s volume of 1,479,029 shares.The stock last traded at $0.26 and had previously closed at $0.23.
The firm has a market capitalization of $5.23, a PE ratio of -0.08 and a beta of 0.77.
ImmunoCellular Therapeutics (NYSEAMERICAN:IMUC) last released its quarterly earnings data on Tuesday, November 21st. The biotechnology company reported ($0.40) EPS for the quarter.
About ImmunoCellular Therapeutics
ImmunoCellular Therapeutics, Ltd. is a clinical-stage biotechnology company. The Company is developing immune-based therapies for the treatment of cancers. The Company’s cancer immunotherapies target cancer stem cells (CSCs), which are the drivers of tumor growth and disease recurrence. Its product candidate is ICT-107, which is in phase III testing.
Receive News & Ratings for ImmunoCellular Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ImmunoCellular Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.